Summary

The Microfluidics market is projected to reach USD 32.67 Billion by 2029 from USD 22.43 in 2024, growing at a CAGR of 7.8% during the forecast period. The market for microfluidics is expanding due to a number of important factors. The growing requirement for point-of-care diagnostics is one of an important factor. The necessity for fast and accurate diagnosis has risen due to the increase in chronic diseases like cancer and diabetes, which is propelling the application of microfluidics in healthcare. Furthermore, the use of microfluidic devices is increasing due to innovations in drug delivery , organ-on-a-chip technology, and personalized medicine. Additionally, the market is driven by the rise in proteomics and genomics associated research.

“Polymers to account for largest market share in 2023.”
The market for microfluidics is propelled by polymers because of their their low costs, ease of production and adaptability. Microfluidic device manufacturing often requires polymers such as polydimethylsiloxane (PDMS), polymethyl methacrylate (PMMA), and cyclic olefin copolymer (COC). These polymers are helpful in the fabrication of microfluidic channels and structures. Moreover, as compared to conventional materials like silicon or glass, polymers are easier to mold and also, enables cheaper manufacturing costs. The biocompatible property of polymers makes them useful for a variety of medical applications, including medication delivery, lab-on-a-chip, and diagnostics. Due to such advantages, polymers accounts for the largest share in the microfluidics market.

“Hospital and Diagnostic Centers to register highest growth rate in the market during the forecast period.”
Various significant factors are propelling the growth of hospitals and diagnostic centers in the microfluidics industry. One important factor is the rising requirement for point-of-care diagnostics, as they provides quick, on-site testing that improves patient outcomes. Microfluidics play a major role in this positive outcome as it offers faster and precise result . Moreover, the requirement for efficacious diagnostics in clinical settings has risen due to the increase in infectious diseases like COVID-19. These equipment decreases cost, expedites testing methods, and improve precision and accuracy of diagnosis.

"Asia Pacific to register highest growth rate in the market during the forecast period."

The highest CAGR was registered by the APAC region throughout the forecast period from 2024-2029. Asia Pacific comprise India, China, Japan, Australia, South Korea and RoAPAC. The demand for innovative technologies is increasing, especially in China, India, and Japan. Microfluidic devices for diagnostic and therapeutic applications are used due to the rise in prevalence of chronic and infectious diseases and the increase in focus on early diagnosis and preventative healthcare. The region's rising pharmaceutical and lifesciences industries are also undertaking research and development initiatives, which increases the requirement for microfluidics in personalized medicine and drug discovery.


A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–30%, Tier 2–42%, and Tier 3– 28%
• By Designation: C-level-- 14%, Director-level–10%, and Others–76%
• By Region: North America–40%, Europe-30%, Asia Pacific–22%, Rest of the World -8%.

Prominent players in this market are Abbott laboratories (US) , Agilent Technologies, Inc. (US), Aignep S.P.A (Italy), biomerieux (France), BD(US), Bio-Rad laboratories, Inc (US), Danaher Corporation (US), Illumina Inc. (US), Parker Hannifin Coporation (US), Thermo Fisher Scientific Inc. (US), SMC Corporation (Japan), Idex Corporation (US), Fortive Corporation (US), Perkinelmer, Inc. (US), F.Hoffmann-LA Roche Ltd (Switzerland), Standard Biotools Inc. (US), Quidelortho Corporation (US), Hologic Inc. (US), Dolomite Microfluidics (UK) and Elveflow (France).

Research Coverage
The report comprise segmentation that covers end users, products, applications, and geographic regions. It also covers the key drivers, restraints, opportunities, and challenges impacting the growth trajectory of the microfluidics market. The research offers stakeholders an in-depth analysis of market potential and challenges, with a focus on major players and competitive landscapes. Moreover, micromarkets are analysed as per their overall impact to the global microfluidics sector, growth patterns, and potential. The analysis forecasts rise in market segment revenues, focusing on five key regions.
Key Benefits of Buying the Report:
The purpose of this research is to assist both new and existing players in the microfluidics market to assess the sustainability of their investments by providing detailed and knowledgeable information. It offers a dataset to assist in making key decisions. This report's potential to facilitate thorough risk evaluation and provide direction for investment decisions is one of its major benefit. Market segmentation according to end-users and geographical areas is provided in the study, that provides precise analysis and insights. It also provide significant trends, obstacles, opportunities, and drivers, giving stakeholders the information they require to make strategic decisions that help in their long-term growth.

The report provides the insights on the following pointers:

Analysis of the key drivers, restraints, opportunities, and challenges affecting the microfluidics market growth: Innovative technology and increase in prevalence of chronic diseases ; increased cost of devices and stringent regulations ; increase in number of diagnostic centers.

Product Development/Innovation: Overview of technologies, research & development ventures and launch of innovative product & service for the microfluidics industry.
Market Development: Details associated with profitable markets: this research studies the microfluidics business in various geographical regions.

Market Diversification: In-depth understanding of innovative products, unexamined regions, recent developments, and expenditures in the microfluidics market.

Competitive Assessment: Detailed analysis of market share, services and products offered and key strategies adopted by prominent players such as Danaher Corporation (US), Illumina Inc. (US), biomerieux (France), Thermo Fisher Scientific Inc. (US) and Abbott laboratories (US).

ページTOPに戻る

Table of Contents

1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.3 MARKET SCOPE 31
1.3.1 MARKETS COVERED 31
1.3.2 INCLUSIONS & EXCLUSIONS 32
1.3.3 YEARS CONSIDERED 33
1.3.4 CURRENCY CONSIDERED 33
1.4 MARKET STAKEHOLDERS 33
1.5 SUMMARY OF CHANGES 34
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH DATA 36
2.2 RESEARCH DESIGN 36
2.2.1 SECONDARY RESEARCH 37
2.2.1.1 Key data from secondary sources 38
2.2.2 PRIMARY RESEARCH 39
2.2.2.1 Key industry insights 40
2.3 MARKET SIZE ESTIMATION METHODOLOGY 41
2.3.1 BOTTOM-UP APPROACH 42
2.3.1.1 Approach 1: Company revenue estimation approach 43
2.3.1.2 Approach 2: Customer-based market estimation 44
2.3.1.3 Approach 3: Top-down approach 45
2.3.1.4 Approach 4: Primary interviews 45
2.3.1.5 Growth forecast 45
2.3.1.6 CAGR projection 46
2.3.2 TOP-DOWN APPROACH 46
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 47
2.5 MARKET SHARE ASSESSMENT 48
2.6 RESEARCH ASSUMPTIONS 48
2.7 RESEARCH LIMITATIONS 49
2.8 RISK ASSESSMENT 49
3 EXECUTIVE SUMMARY 50
4 PREMIUM INSIGHTS 54
4.1 MICROFLUIDICS MARKET OVERVIEW 54
4.2 ASIA PACIFIC: MICROFLUIDICS MARKET, BY END USER AND COUNTRY (2023) 55
 
4.3 MICROFLUIDICS MARKET, BY REGION 56
4.4 GEOGRAPHIC SNAPSHOT OF MICROFLUIDICS MARKET 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS 57
5.2.1 DRIVERS 58
5.2.1.1 Growing requirement for point-of-care testing 58
5.2.1.2 Rising technological advancements 59
5.2.1.3 Increasing focus on data precision and accuracy 60
5.2.1.4 Economic benefits associated with microfluidics 60
5.2.1.5 Portability with microfluidic chip miniaturization 61
5.2.1.6 Rising demand for effective sample analysis 61
5.2.2 RESTRAINTS 62
5.2.2.1 Stringent regulatory approval process 62
5.2.2.2 Integration of microfluidics into current workflow 62
5.2.3 OPPORTUNITIES 63
5.2.3.1 Emergence of 3D cell culture systems 63
5.2.3.2 Growth potential of emerging economies 63
5.2.3.3 Use of microfluidics in life sciences & pharmaceutical industries 64
5.2.4 CHALLENGES 65
5.2.4.1 Low adoption of microfluidic devices among end users 65
5.3 INDUSTRY TRENDS 65
5.3.1 E-HEALTH DIAGNOSTICS 65
5.3.2 INTEGRATION OF MICROFLUIDICS WITH 3D PRINTING 66
5.3.3 R&D INVESTMENTS FOR PRODUCT DEVELOPMENT 66
5.4 PORTER’S FIVE FORCES ANALYSIS 69
5.4.1 THREAT OF NEW ENTRANTS 70
5.4.2 THREAT OF SUBSTITUTES 70
5.4.3 BARGAINING POWER OF SUPPLIERS 70
5.4.4 BARGAINING POWER OF BUYERS 70
5.4.5 INTENSITY OF COMPETITIVE RIVALRY 71
5.5 KEY STAKEHOLDERS & BUYING CRITERIA 71
5.5.1 KEY STAKEHOLDERS IN BUYING PROCESS 71
5.5.2 BUYING CRITERIA 72
5.6 REGULATORY LANDSCAPE 73
5.6.1 NORTH AMERICA 73
5.6.1.1 US 73
5.6.1.2 Canada 74
5.6.2 EUROPE 75
5.6.3 ASIA PACIFIC 77
5.6.3.1 Japan 77
5.6.3.2 China 78
5.6.3.3 India 78
5.6.4 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 79
5.7 REIMBURSEMENT SCENARIO 82
5.8 ECOSYSTEM ANALYSIS 83
5.9 VALUE CHAIN ANALYSIS 85
5.9.1 RESEARCH & DEVELOPMENT 85
5.9.2 RAW MATERIAL PROCUREMENT & MANUFACTURING 86
5.9.3 MARKETING & SALES, DISTRIBUTION, AND POST-SALES SERVICES 86
5.10 SUPPLY CHAIN ANALYSIS 87
5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 88
5.12 IMPACT OF GEN AI ON MICROFLUIDICS MARKET 89
5.13 PATENT ANALYSIS 89
5.13.1 PATENT PUBLICATION TRENDS FOR MICROFLUIDICS 90
5.13.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 90
5.14 TRADE ANALYSIS 95
5.14.1 IMPORT DATA 95
5.14.2 EXPORT DATA 96
5.15 TECHNOLOGY ANALYSIS 96
5.15.1 KEY TECHNOLOGIES 97
5.15.1.1 Biosensor elements 97
5.15.1.2 Materials science 97
5.15.1.3 Microfabrication 98
5.15.1.4 Direct-writing 98
5.15.2 COMPLEMENTARY TECHNOLOGIES 99
5.15.2.1 MEMS 99
5.15.2.1.1 Green microfluidics 99
5.15.2.1.2 Microsensors/transducers 99
5.15.3 ADJACENT TECHNOLOGIES 100
5.15.3.1 3D inkjet printing 100
5.15.3.2 Lab-on-fiber 100
5.16 KEY CONFERENCES & EVENTS 101
5.17 PRICING ANALYSIS 102
5.17.1 AVERAGE SELLING PRICE TREND, BY REGION 102
5.17.2 AVERAGE SELLING PRICE TREND OF TOP 3 APPLICATIONS, BY KEY PLAYER 105
5.18 UNMET NEEDS/END-USER EXPECTATIONS IN MICROFLUIDICS MARKET 105
5.19 CASE STUDY ANALYSIS 106
5.19.1 CASE STUDY 1: MULTIPLEX MICROFLUIDIC CIRCUIT FOR BLOOD
VESSEL-ON-A-CHIP PERFUSION USING FLOWEZ 106
5.19.2 CASE STUDY 2: MICROFLUIDIC SYSTEM FOR ROBOTIC HAND PLAYING NINTENDO 107
5.19.3 CASE STUDY 3: 3D-PRINTED MICROFLUIDIC DEVICES USING POLYJET TECHNOLOGY 107
5.20 INVESTMENT & FUNDING SCENARIO 108
6 MICROFLUIDICS MARKET, BY PRODUCT 110
6.1 INTRODUCTION 111
6.2 MICROFLUIDICS-BASED DEVICES 111
6.2.1 HIGH UPTAKE OF POC TESTING AND ORGAN-ON-A-CHIP SYSTEMS
TO PROPEL MARKET 111
6.3 MICROFLUIDIC COMPONENTS 112
6.3.1 MICROFLUIDIC COMPONENTS, BY TYPE 113
6.3.1.1 Microfluidic chips 114
6.3.1.1.1 Chips to account for largest share of components market 114
6.3.1.2 Flow & pressure sensors 116
6.3.1.2.1 Utilization in lab diagnostics & research applications to drive market 116
6.3.1.3 Flow & pressure controllers 118
6.3.1.3.1 Cost-effectiveness and durability to boost demand 118
6.3.1.4 Microfluidic valves 119
6.3.1.4.1 Technological advancements to support market growth 119
6.3.1.5 Micropumps 123
6.3.1.5.1 Wide usage in drug delivery and glucose injections to fuel uptake 123
6.3.1.6 Microneedles 125
6.3.1.6.1 Miniscule size and painless patch application procedure to boost demand 125
6.3.1.7 Other microfluidic components 126
6.3.2 MICROFLUIDIC COMPONENTS, BY MATERIAL 127
6.3.2.1 Silicon 127
6.3.2.1.1 High precision and durability to boost demand 127
6.3.2.2 Polymers 128
6.3.2.2.1 Polymethyl Methacrylate (PMMA) 129
6.3.2.2.1.1 Durable alternative to glass to fuel uptake 129
6.3.2.2.2 Polydimethylsiloxane (PDMS) 130
6.3.2.2.2.1 Limited compatibility with specific solvents and acids to limit market adoption 130
6.3.2.2.3 Cyclic Olefin Copolymers 131
6.3.2.2.3.1 Low water absorption and enhanced electrical insulation properties to boost demand 131
6.3.2.2.4 Other polymers 132
6.3.2.3 Glass 133
6.3.2.3.1 High cost and brittleness to restrain market 133
 
7 MICROFLUIDICS MARKET, BY APPLICATION 134
7.1 INTRODUCTION 135
7.2 IVD 135
7.2.1 CLINICAL DIAGNOSTICS 137
7.2.1.1 Growing focus on early disease detection to drive market 137
7.2.2 POINT-OF-CARE TESTING (POCT) 138
7.2.2.1 High uptake of lab-on-a-chip technologies to fuel uptake 138
7.2.3 VETERINARY DIAGNOSTICS 139
7.2.3.1 Detection of toxins in food through LOC systems to support market growth 139
7.3 PHARMACEUTICAL & LIFE SCIENCE RESEARCH 140
7.3.1 LAB ANALYTICS 141
7.3.1.1 Proteomic analysis 142
7.3.1.1.1 Utilization of lab-on-a-chip devices for therapeutic development to drive market 142
7.3.1.2 Genomic analysis 143
7.3.1.2.1 Growing focus on NGS and digital PCR to boost demand 143
7.3.1.3 Cell-based assays 144
7.3.1.3.1 Drug-screening for cross-reaction & toxicity testing to support market growth 144
7.3.1.4 Capillary electrophoresis 145
7.3.1.4.1 Growing applications for environmental monitoring and clinical diagnostics to fuel uptake 145
7.3.2 MICRODISPENSING 146
7.3.2.1 Suitability for low-viscosity applications to support market growth 146
7.3.3 MICROREACTORS 147
7.3.3.1 High uptake by leading companies for process optimization to fuel market 147
7.4 THERAPEUTICS 148
7.4.1 DRUG DELIVERY 149
7.4.1.1 Utilization of microneedles for painless and precise delivery to drive market 149
7.4.2 WEARABLE DEVICES 150
7.4.2.1 Integration of microfluidics-based wearable devices to support market growth 150
8 MICROFLUIDICS MARKET, BY END USER 152
8.1 INTRODUCTION 153
8.2 HOSPITALS AND DIAGNOSTIC CENTERS 153
8.2.1 AVAILABILITY OF TECHNOLOGICALLY ADVANCED EQUIPMENT AND FOCUS ON EARLY DISEASE DIAGNOSIS TO BOOST DEMAND 153
8.3 ACADEMIC & RESEARCH INSTITUTES 154
8.3.1 INVESTMENTS IN BIOMEDICAL & LIFE SCIENCE RESEARCH TO SUPPORT MARKET GROWTH 154
8.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 157
8.4.1 GROWING FOCUS ON BIOMARKER & DRUG DISCOVERY TO PROPEL MARKET 157
9 MICROFLUIDICS MARKET, BY REGION 159
9.1 INTRODUCTION 160
9.2 NORTH AMERICA 160
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 161
9.2.2 US 167
9.2.2.1 High healthcare expenditure and wide adoption of technologically advanced products to drive market 167
9.2.3 CANADA 169
9.2.3.1 Government funds and focus on research to support market growth 169
9.3 EUROPE 171
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 171
9.3.2 GERMANY 176
9.3.2.1 Growing focus on proteomics & genomics research to drive market 176
9.3.3 FRANCE 179
9.3.3.1 Favorable government support for R&D to drive market 179
9.3.4 UK 181
9.3.4.1 Rising cases of chronic diseases and increasing demand for POC testing to boost demand 181
9.3.5 ITALY 183
9.3.5.1 Innovative development of microfluidic chips to boost demand 183
9.3.6 SPAIN 185
9.3.6.1 Growth in pharmaceutical industry to fuel uptake 185
9.3.7 REST OF EUROPE 187
9.4 ASIA PACIFIC 189
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 190
9.4.2 CHINA 196
9.4.2.1 Growing focus on nanotechnology to drive market 196
9.4.3 JAPAN 198
9.4.3.1 High investments in academic research activities to propel market 198
9.4.4 INDIA 200
9.4.4.1 Increasing prevalence of CVD and diabetes to support market growth 200
9.4.5 AUSTRALIA 203
9.4.5.1 Rising incidence of infectious diseases to fuel uptake 203
9.4.6 SOUTH KOREA 205
9.4.6.1 Increasing R&D expenditure to drive growth 205
9.4.7 REST OF ASIA PACIFIC 208
 
9.5 LATIN AMERICA 209
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 209
9.5.2 BRAZIL 214
9.5.2.1 Increasing development of disease diagnostics kits to fuel uptake 214
9.5.3 MEXICO 216
9.5.3.1 Rising prevalence of chronic diseases to boost demand for POC testing 216
9.5.4 REST OF LATIN AMERICA 218
9.6 MIDDLE EAST & AFRICA 220
9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 221
9.6.2 GCC COUNTRIES 225
9.6.2.1 Adoption of advanced microfluidic devices to support market growth 225
9.6.3 REST OF MIDDLE EAST & AFRICA 227
10 COMPETITIVE LANDSCAPE 230
10.1 INTRODUCTION 230
10.2 KEY PLAYER STRATEGY/RIGHT TO WIN 230
10.3 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN MICROFLUIDICS MARKET 230
10.4 REVENUE ANALYSIS 231
10.5 MARKET SHARE ANALYSIS BY KEY PLAYERS,2023 232
10.6 RANKING OF KEY MARKET PLAYERS 234
10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 234
10.7.1 STARS 234
10.7.2 EMERGING LEADERS 234
10.7.3 PERVASIVE PLAYERS 235
10.7.4 PARTICIPANTS 235
10.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 236
10.7.5.1 Company footprint 236
10.7.5.2 Product footprint 237
10.7.5.3 Application footprint 238
10.7.5.4 End-user footprint 239
10.7.5.5 Region footprint 240
10.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 241
10.8.1 PROGRESSIVE COMPANIES 241
10.8.2 RESPONSIVE COMPANIES 241
10.8.3 DYNAMIC COMPANIES 241
10.8.4 STARTING BLOCKS 241
10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 243
10.8.5.1 Detailed list of key startup/SME players 243
10.8.5.2 Competitive benchmarking of key emerging players/startups 244
 
10.9 COMPANY VALUATION & FINANCIAL METRICS 245
10.9.1 FINANCIAL METRICS 245
10.9.2 COMPANY VALUATION 245
10.10 BRAND/PRODUCT COMPARATIVE ANALYSIS 246
10.11 COMPETITIVE SCENARIO 247
10.11.1 PRODUCT LAUNCHES & APPROVALS 247
10.11.2 DEALS 248
10.11.3 EXPANSIONS 249
10.11.4 OTHER DEVELOPMENTS 249
11 COMPANY PROFILES 250
11.1 KEY PLAYERS 250
11.1.1 DANAHER CORPORATION 250
11.1.1.1 Business overview 250
11.1.1.2 Products offered 252
11.1.1.3 Recent developments 253
11.1.1.3.1 Deals 253
11.1.1.3.2 Expansions 254
11.1.1.4 MnM view 254
11.1.1.4.1 Key strengths 254
11.1.1.4.2 Strategic choices 254
11.1.1.4.3 Weaknesses & competitive threats 254
11.1.2 ILLUMINA, INC. 255
11.1.2.1 Business overview 255
11.1.2.2 Products offered 257
11.1.2.3 Recent developments 258
11.1.2.3.1 Product launches & approvals 258
11.1.2.3.2 Deals 258
11.1.2.4 MnM view 260
11.1.2.4.1 Key strengths 260
11.1.2.4.2 Strategic choices 260
11.1.2.4.3 Weaknesses & competitive threats 260
11.1.3 BIOMÉRIEUX 261
11.1.3.1 Business overview 261
11.1.3.2 Products offered 263
11.1.3.3 Recent developments 263
11.1.3.3.1 Product launches & approvals 263
11.1.3.4 MnM view 264
11.1.3.4.1 Key strengths 264
11.1.3.4.2 Strategic choices 264
11.1.3.4.3 Weaknesses & competitive threats 264
 
11.1.4 THERMO FISHER SCIENTIFIC INC. 265
11.1.4.1 Business overview 265
11.1.4.2 Products offered 267
11.1.4.3 Recent developments 268
11.1.4.3.1 Product launches & approvals 268
11.1.4.3.2 Deals 270
11.1.4.3.3 Expansions 271
11.1.4.4 MnM view 271
11.1.4.4.1 Key strengths 271
11.1.4.4.2 Strategic choices 271
11.1.4.4.3 Weaknesses & competitive threats 271
11.1.5 ABBOTT LABORATORIES 272
11.1.5.1 Business overview 272
11.1.5.2 Products offered 274
11.1.5.3 MnM view 275
11.1.5.3.1 Key strengths 275
11.1.5.3.2 Strategic choices 275
11.1.5.3.3 Weaknesses & competitive threats 275
11.1.6 PARKER HANNIFIN CORP 276
11.1.6.1 Business overview 276
11.1.6.2 Products offered 278
11.1.7 SMC CORPORATION 281
11.1.7.1 Business overview 281
11.1.7.2 Products offered 282
11.1.7.3 Recent developments 285
11.1.7.3.1 Product launches 285
11.1.8 IDEX CORPORATION 287
11.1.8.1 Business overview 287
11.1.8.2 Products offered 288
11.1.8.3 Recent developments 290
11.1.8.3.1 Deals 290
11.1.9 FORTIVE 291
11.1.9.1 Business overview 291
11.1.9.2 Products offered 292
11.1.10 PERKINELMER INC. 295
11.1.10.1 Business overview 295
11.1.10.2 Products offered 297
11.1.10.3 Recent developments 298
11.1.10.3.1 Product launches 298
11.1.10.3.2 Deals 299
 
11.1.11 AGILENT TECHNOLOGIES, INC. 300
11.1.11.1 Business overview 300
11.1.11.2 Products offered 301
11.1.11.3 Recent developments 303
11.1.11.3.1 Product launches 303
11.1.11.3.2 Deals 304
11.1.11.3.3 Expansions 304
11.1.12 BIO-RAD LABORATORIES, INC. 305
11.1.12.1 Business overview 305
11.1.12.2 Products offered 307
11.1.12.3 Recent developments 308
11.1.12.3.1 Product launches 308
11.1.12.3.2 Deals 309
11.1.13 BECTON, DICKINSON AND COMPANY 310
11.1.13.1 Business overview 310
11.1.13.2 Products offered 312
11.1.13.3 Recent developments 314
11.1.13.3.1 Product launches & approvals 314
11.1.13.3.2 Deals 315
11.1.13.3.3 Expansions 316
11.1.14 F. HOFFMANN-LA ROCHE LTD. 317
11.1.14.1 Business overview 317
11.1.14.2 Products offered 318
11.1.14.3 Recent developments 319
11.1.14.3.1 Product launches & approvals 319
11.1.14.3.2 Deals 320
11.1.15 STANDARD BIOTOOLS 321
11.1.15.1 Business overview 321
11.1.15.2 Products offered 323
11.1.15.3 Recent developments 324
11.1.15.3.1 Product launches & approvals 324
11.1.15.3.2 Deals 325
11.1.16 QUIDELORTHO CORPORATION 326
11.1.16.1 Business overview 326
11.1.16.2 Products offered 328
11.1.16.3 Recent developments 329
11.1.16.3.1 Product approvals 329
11.1.16.3.2 Deals 330
11.1.16.3.3 Expansions 330
 
11.1.17 HOLOGIC, INC. 331
11.1.17.1 Business overview 331
11.1.17.2 Products offered 333
11.1.17.3 Recent developments 333
11.1.17.3.1 Product approvals 333
11.1.17.3.2 Deals 333
11.1.18 AIGNEP S.P.A. 334
11.1.18.1 Business overview 334
11.1.18.2 Products offered 335
11.1.18.3 Recent developments 335
11.1.18.3.1 Deals 335
11.1.19 DOLOMITE MICROFLUIDICS 336
11.1.19.1 Business overview 336
11.1.19.2 Products offered 337
11.1.19.3 Recent developments 341
11.1.19.3.1 Product launches & approvals 341
11.1.19.3.2 Deals 341
11.1.19.3.3 Other developments 341
11.1.20 ELVEFLOW 342
11.1.20.1 Business overview 342
11.1.20.2 Products offered 342
11.2 OTHER PLAYERS 344
11.2.1 NANOSTRING TECHNOLOGIES 344
11.2.2 NORTIS INC. 345
11.2.3 INNOVATIVE BIOCHIPS, LLC 346
11.2.4 FLUIDIC ANALYTICS 347
11.2.5 UFLUIDIX 348
11.2.6 HORIBA 349
11.2.7 MICRONIT B.V. 350
12 APPENDIX 351
12.1 DISCUSSION GUIDE 351
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 357
12.3 CUSTOMIZATION OPTIONS 359
12.4 RELATED REPORTS 359
12.5 AUTHOR DETAILS 360